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Abstract
Introduction: The present study aimed to explore a possible role for IL-21 producing Th-cells in the
immunopathogenesis of granulomatosis with polyangiitis (GPA).
Methods: Peripheral blood from 42 GPA patients in remission and 29 age-matched healthy controls (HCs) were
stimulated in vitro, and the frequencies of IL-21 producing Th-cells were determined by flow cytometry. Since
Th17-cells produce a low level of IL-21, IL-17 was also included in the analysis. Given that IL-21 is a hallmark
cytokine for T follicular helper cells (TFH), we next evaluated the expression of their key transcription factor BCL-6
by RT-PCR and flow cytometry. To investigate the effect of IL-21 on autoantibody-production, PBMCs from GPA
patients were stimulated in vitro with BAFF/IL-21 and total IgG and ANCA levels were measured in supernatants. In
addition, the expression of IL-21-receptor on B-cells was analyzed.
Results: Percentages of IL-21 producing Th-cells were significantly elevated in GPA-patients compared to HCs, and
were restricted to ANCA-positive patients. The expression of BCL-6 was significantly higher in ANCA-positive
GPA-patients, as compared with ANCA-negative patients and HCs. IL-21 enhanced the production of IgG and
ANCA in vitro in stimulated PBMCs from GPA patients. No difference was found in the expression of the IL-21-
receptor on B-cells between ANCA-negative patients, ANCA-positive patients, and HCs.
Conclusion: The increased frequency of circulating IL-21 producing Th-cells in ANCA-positive GPA patients and the
stimulating capacity of IL-21 on ANCA-production suggest a role for these cells in the immunopathogenesis of
GPA. Blockade of IL-21 could constitute a new therapeutic strategy for GPA.
Introduction
Granulomatosis with polyangiitis (GPA) is an autoimmune
vasculitis of small- to medium-sized blood vessels, asso-
ciated with the presence of circulating anti-neutrophil
cytoplasmic autoantibodies (ANCA) that are mainly direc-
ted against proteinase 3 [1-3]. Histopathologically, GPA is
characterized by granulomatous inflammation and pauci-
immune vasculitis, including necrotizing crescentic
glomerulonephritis.
Although the production of ANCA is directly attributa-
ble to autoreactive B-cells, there is extensive evidence
that T-cells play a critical role in GPA as well. The
immunoglobulin (Ig)G subclass distribution of ANCA,
with a preponderance of the IgG1 and IgG4 subclasses,
suggests a T-cell-dependent immune response [4]. Infil-
trating T-cells in granulomatous lesions and persistent
T-cell activation have been observed in GPA patients
[5,6]. In addition, an aberrant T-cell phenotype and
impaired regulatory T-cell function are also reported in
GPA patients in remission [7-9], suggesting that even
during remission, the immune system is dysregulated.
Moreover, T-helper (Th) cell polarization with an
increase in Th17 cells has been demonstrated [10,11].
Th17 cells and their cytokine IL-17 have been shown to
play a critical role in many inflammatory diseases.
In addition to IL-17, Th17 cells can produce IL-21, a
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cytokine that is largely responsible for B-cell class switch-
ing and antibody production, and which induces differen-
tiation of B-cells towards plasma cells by synergizing with
B-cell activating factor (BAFF)[12,13]. Therefore, it is
conceivable that IL-21 may contribute to the production
of pathogenic autoantibodies in GPA.
Multiple studies in animal models indicate a pivotal role
of IL-21 in the pathogenesis of autoimmune diseases.
Studies in arthritis models have shown that blockade of
IL-21 activity reduces joint inflammation and destruction
[14]. Subsequent investigations demonstrated that block-
ing of the IL-21 pathway reduces levels of anti-dsDNA
autoantibodies and prevents renal disease in mouse mod-
els of systemic lupus erythematosus (SLE) [15]. In addi-
tion, mice deficient in IL-21-receptor expression were
found to be protected to a large extent against the devel-
opment of inflammatory bowel disease (IBD) and type-I
diabetes [16,17]. Interestingly, recent genome-wide asso-
ciation studies have provided convincing evidence that
genetic variants in the region on chromosome 4q27 that
harbor the IL-21 and IL-2 genes are associated with
chronic inflammatory disorders, including SLE, IBD and
psoriasis [18-20]. Thus, IL-21 seems to play an important
role in autoimmune diseases in general and could consti-
tute a novel target for therapy.
IL-21 is produced mainly by activated CD4+ Th-cells.
Recent studies have demonstrated that IL-21, besides its
production by Th17 cells, is predominantly secreted by a
distinct Th-cell lineage, termed follicular helper T-cells
(TFH) that express the transcription factor BCL-6 and are
considered to be specialized providers of B-cell help [21].
Expansion of circulating T-cells resembling TFH cells has
been reported in patients with SLE and in patients with
rheumatoid arthritis [22-24]. To date, no study has inves-
tigated the role of IL-21-producing Th-cells in GPA.
Therefore, this study aimed to assess the frequency of IL-
21-producing Th-cells, and to evaluate whether TFH cells
or Th17 cells are the major source of IL-21 in GPA
patients. For this purpose, we examined the expression of
both IL-21 and IL-17 in circulating CD4+ T-cells of
patients with GPA. To improve our understanding of the
role of IL-21-producing Th cells in autoantibody produc-
tion we assessed their frequencies in ANCA-positive and
ANCA-negative patients, and studied effects of IL-21 on
Ig and ANCA production in vitro.
Methods
Study population
Forty-two patients with GPA and 29 age- and sex-
matched healthy controls (HC) (18 male, 11 female,
mean age 56 (SD ± 13) years, range 26 to 72 years, P =
0.16) were included in this study. The diagnosis of GPA
was established according to the definitions of the Cha-
pel Hill Consensus Conference and patients fulfilled the
classification criteria of the American College of Rheu-
matology (ACR)[25,26]. Only patients without clinical
signs and symptoms of active vasculitis and considered
to be in complete remission, as indicated by a score of
zero on the Birmingham Vasculitis Activity Score
(BVAS), were included in the study [27]. Serostatus for
ANCA was followed for several months in all patients,
and patients with a stable serostatus for ANCA (positive
or negative) for at least 3 months were included in this
study. Based on these criteria, 23 patients were positive
for PR3-ANCA, whereas 19 were ANCA-negative. There
was history of generalized disease including renal invol-
vement in 27 patients, and 15 patients had localized dis-
ease, which had been confined to the upper and/or lower
respiratory tract. None of the patients and controls had
infection at the time of sampling. Eleven GPA-patients
(eight ANCA-positive, and three ANCA-negative) were
treated with maintenance immunosuppressive therapy at
the time of blood sampling. Four of them were treated
with only azathioprine (25 to 100 mg/day), one patient
with mycophenolate mofetil (1500 mg/day), and six
patients received prednisolone (5 to 10 mg/day) in com-
bination with azathioprine (125 mg/day). Participants in
rituximab trials were excluded from the present study.
The main clinical and laboratory data from the patients
are summarized in Table 1. All patients and healthy indi-
viduals provided informed consent and the study was
approved by the local Medical Ethics Committee of the
University Medical Centre Groningen, University of Gro-
ningen (NL).
Measurement of ANCA titres and specificity
ANCA titers were measured by indirect immunofluores-
cence (IIF) on ethanol-fixed human granulocytes accord-
ing to standard procedures as previously described [28].
ANCA titers higher than 1:40 were considered positive.
Table 1 Clinical and laboratory characteristics of patients
with granulomatosis with polyangiitis (GPA) at the time
of blood sampling
Characteristic Value
Patients, number 42
Male/female, number 26/16
Age, mean ± SD (range), years 59 ± 14 (28, 81)
Localized/generalized GPA, number 15/27
Positive/negative for PR3-ANCA†, number 23/19
Receiving/not receiving treatment††, number 11/31
Relapses, median (range), number 0 (0, 5)
Disease duration, median (range), months 112 (20, 334)
†Patients were considered to be ANCA-positive when ANCA-titres by IIF were
greater than 1:40. ††Four patients were treated with azathioprine only, one
with mycophenolate mofetil, and six patients received prednisolone in
combination with azathioprine. GPA, granulomatosis with polyangiitis; PR3,
proteinase 3; ANCA, antineutrophil cytoplasmic antibody.
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ANCA antigenic specificity was determined using an in-
house capture ELISA as described before [29,30]. Briefly,
a 96-well plate was coated with goat-anti-mouse Ig for
48 hours. After washing, plates were incubated with
mouse monoclonal antibody against human PR3 for
2 hours. After washing, the plate was incubated over-
night at 4°C with an extract of human azurophilic gran-
ules, which were isolated from neutrophils of healthy
donors. Further, serial dilutions of serum (with a start-
ing dilution of 1:100) were incubated for 1 hour. The
plate was washed, and the captured antibodies were
detected with purified F(ab)2 goat-anti-human IgG
conjugated to alkaline phosphatase. P-nitrophenyl-
phosphate disodium was used as a substrate, and the
optical density was measured at 405 nm.
Antibodies used in flow cytometry
The following conjugated antibodies were used in flow
cytometry: allophycocyanin (APC)-conjugated anti-CD3
(clone UCHT1), peridin chlorophyll protein (PerCP)-
conjugated anti-CD8 (clone SK1), phycoerythrin (PE)-
conjugated anti-IL-21-receptor (clone 17A12), and
PerCP-conjugated anti-CD19 (clone 4G7), all purchased
from Becton & Dickinson (Amsterdam, The Nether-
lands); PE-conjugated anti-IL-21 (clone eBio3A3-N2),
Alexa Fluor® 488 (A488)-conjugated anti-IL-17 (clone
eBio64DEC17), and A488-conjugated anti-FoxP3 (clone
PCH101), all purchased from eBioscience (San Diego,
CA, USA); and PE-conjugated anti-BCL-6 (clone
IC5046P) obtained from R&D Systems (Minneapolis,
MN, USA).
Sample preparation and in vitro stimulation
Lithium-heparinized venous blood was obtained from
patients and healthy donors. Immediately after sampling,
400 μL blood was mixed with 400 μL RPMI1640 (Cam-
brex Bio Science, Verviers, Belgium), supplemented with
50 μg/ml gentamycin (Gibco, Scotland, UK), and
aliquoted in two 5-mL polypropylene tubes (BD Bios-
ciences, Amsterdam, The Netherlands) (400 μL per tube).
Diluted blood samples were stimulated 4 hours with
50 ng/mL phorbol myristate acetate (PMA; Sigma-Aldrich,
Steinheim, Germany) and 2 nM calcium ionophore (Ca-Io;
Sigma-Aldrich). As a negative control, one sample was
kept in medium only without stimulation. For inhibiting
cytokine release from the cells, 10 μg/ml of brefeldin A
(Sigma-Aldrich) was added to each sample.
Intracellular fluorescence-activated cell sorter (FACS)-
staining for cytokines
After stimulation cells were washed in wash buffer (PBS,
5% fetal bovine serum (FBS), 0.1% sodium azide (Merk,
Germany)] and stained with PerCP-conjugated anti-CD8
and APC-conjugated anti-CD3 for 15 minutes at room
temperature. Cells were fixed with 100 μL Reagent A (Cal-
tag/Invitrogen., Breda, The Netherlands) for 10 minutes.
After washing, the pellet was resuspended in 100 μL per-
meabilization Reagent B (Caltag/Invitrogen) and labeled
with A488-conjugated anti-IL-17 and PE-conjugated anti-
IL-21 for 20 minutes in the dark. After staining, the cells
were washed and immediately analyzed on the FACS-
Calibur flow cytometer (Becton & Dickinson). Data were
collected for 2 × 105 cells, and plotted using the Win-List
software package (Verity Software House Inc, ME, USA)
ME, USA). Because stimulation reduces surface expression
of CD4 on T-cells, CD4+T-cells were identified indirectly
by gating on CD3-positive and CD8-negative lymphocytes.
Gated CD4+ T-cells were further displayed as a dot plot for
evaluation of intracellular cytokine production. The unsti-
mulated control sample was used as a guide for setting
the linear gates to discriminate positive and negative
populations.
Intracellular staining for transcription factors
Peripheral blood mononuclear cells (PBMCs) from GPA
patients and HCs were prepared from heparinized venous
blood by density-gradient centrifugation on Lymphoprep
(Axis-Shield PoC AS, Oslo, Norway). Cells recovered from
the gradient interface were washed twice in PBS and
stained for BCL-6 and FoxP3 according to the manufac-
turer’s instructions (eBioscience staining set for transcrip-
tion factors). Briefly, PBMCs were adjusted to 1 × 106 cells
in 100 μL and incubated with appropriate concentration
of APC-conjugated anti-CD3 and PerCP-conjugated anti-
CD8 for 30 minutes at 4°C in the dark, followed by fixa-
tion and permeabilizaion in Fix/Perm buffer (eBioscience)
for 45 minutes. Cells were then washed twice with 1 ×
permeabilization buffer (eBioscience), and stained with
PE-conjugated anti-BCL-6 and A488-conjugated anti-
FoxP3. After incubation for 30 minutes in the dark, the
cell suspension was washed and immediately analyzed on
the FACS-Calibur flow cytometer (Becton & Dickinson).
Lymphocytes were gated by forward and side scatter pat-
terns, and plotted using the Win-List software package
(Verity Software House Inc). Isotype matched control anti-
bodies of irrelevant specificity were obtained from
eBioscience and R&D systems.
Immunofluorescent surface staining for IL-21R on B-cells
Fresh blood samples from GPA patients and HCs were
labeled with PE-conjugated anti-IL21R, and PerCP-con-
jugated anti-CD19 for 15 minutes in the dark. Cells
were successively treated with 2 mL diluted FACS lysing
solution (BD, Amsterdam, The Netherlands) for 10 min-
utes and then washed twice in wash buffer and immedi-
ately analyzed by flow cytometry.
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RNA isolation and real-time reverse transcription (RT)-PCR
Erythrocytes were lysed and leukocytes were fixed and
washed twice in 1% BSA. RNA was isolated from total
leukocytes with TRIzol reagent (Invitrogen) according to
the manufacturer’s instructions. DNAse treatment
(Ambion, Huntingdon, Cambridgeshire, UK) was per-
formed and subsequently cDNA was synthesized using
M-MLV reverse transcriptase and oligo (dT) 14 to 18 as
primer. For measurement of mRNA for BCL-6 and gly-
ceraldehyde-3-phosphate dehydrogenase (GAPDH), 1 μL
of cDNA in triplicate was used for amplification by the
Taqman RT-PCR system (ABI Prism 7900HT Sequence
Detection System, Applied Biosystems, Foster City, CA,
USA) with specific Taqman primers/probes (BCL-6 (Hs
00153368_m1) and GAPDH (Hs 99999905_m1), Applied
Biosystems). Amplification was performed using stan-
dard conditions and calculations of fold induction were
performed. We normalized gene expression to GAPDH
and expressed values relative to control using the ΔΔCT
(cycle threshold) method.
Cell stimulation and total IgG production
PBMCs recovered from the gradient interface were
washed twice in PBS and adjusted to 106 cells/mL in
RPMI 1640 (Lonza, Basel, Switzerland) supplemented
with 10% FCS (Lonza, Switzerland) and 50 μg/mL gen-
tamicin (GIBCO, Invitrogen). Cells were cultured in the
presence of 100 ng/mL rhIL-21 (ImmunoTools GmbH,
Friesoythe, Germany) and/or 100 ng/mL rhBAFF
(PeproTech, NJ, USA) for 12 days at 37°C with 5% CO2.
After 12 days, culture supernatants were collected and
total IgG was measured using an in-house ELISA as
described previously [31]. Briefly, Costar 96-well ELISA
plates were coated with 2 mg/mL goat anti-human-Ig
antibody (Southern Biotech, Birmingham, AL, USA) in
carbonate buffer (0.01 M, pH 9.6). Plates were washed
with washing buffer (0.025 M Tris-HCl, 0.15 M NaCl,
0.05% Tween-20) and blocked for 1 hour with blocking/
incubation-buffer (0.05 M Tris-HCl, 0.3 M NaCl, 0.05%
Tween-20, 1% BSA). Cell culture supernatants were
diluted in incubation buffer. Purified human IgG with a
known concentration was used as a standard sample.
The bound IgG was detected with goat-anti-human-IgG
antibody conjugated with alkaline phosphatase (Sigma,
St Louis, MO, USA). P-nitrophenyl-phosphate disodium
was used as substrate and optical density was read at
405 nm using an Emax microplate reader (Molecular
Devices, Silicon Valley, CA, USA).
Measurement of in vitro production of PR3-ANCA
In vitro PR3-ANCA IgG production in PBMC culture
supernatants was measured by Phadia ImmunoCAP®
250 analyzer (Thermo Fisher Scientific, MA, USA) using
ELiA™ PR3, and the levels of PR3-ANCA IgG produc-
tion were expressed in response units (RU).
Statistical analysis
Data are presented as median values unless stated other-
wise. The nonparametric Mann-Whitney U-test was
used to compare data from patients with those of HCs.
The Wilcoxon matched pairs test was used for intra-
individual comparison. Correlations were assessed using
Spearman’s rank correlation coefficient. Two-tailed
P-values lower than 0.05 were considered statistically
significant.
Results
Increased percentage of circulating IL-21+IL-17- cells in
ANCA-positive GPA patients compared to ANCA-negative
patients and healthy controls
We initially determined the frequency of IL-21-producing
CD4 T-cells in the peripheral blood of GPA patients (n =
42) and HCs (n = 29) after in vitro stimulation. The per-
centage of circulating IL-21+ Th-cells was significantly
higher in GPA patients compared with the control group
(Figure 1B). Of note, Th17 cells may produce IL-21 in
addition to their signature cytokine IL-17. Since Th17
cells are increased in GPA patients [10,11], we next
extended our analysis to investigate whether increased
IL-21+ Th-cells in GPA patients resulted from an increase
in Th17 cells. To this end, IL-17 staining was included in
the analysis to determine what percentage of the total
IL-21+ Th-cells are Th17 cells. Using this approach, we
assessed the frequency of IL-21+IL-17-, IL-21+IL-17+, and
IL-21-IL-17+ cells within the CD4 T-cells in GPA patients
and HCs. As shown in Figure (1C, D and 1E), GPA
patients in remission had a significantly higher percentages
of circulating IL-21+IL-17-, IL-21+IL-17+, and IL-21-IL-17+
cells compared with the control group. However, the
majority of circulating CD4+ T-cells that produced only
IL-21 were distinct from Th17 cells, that is, negative for
IL-17. To assess the possible role of IL-21+IL-17- Th-cells
in ANCA production, we compared their percentage
between patients who were ANCA-positive (n = 23; IIF
titer >1:40) or ANCA-negative (n = 19) at the time of
inclusion. Significant increases in the frequencies of IL-21
+IL-17- Th-cells were observed in ANCA-positive patients
in comparison with HCs and ANCA-negative patients,
whereas no significant difference was found between
ANCA-negative patients and HCs (Figure 1F). In contrast,
the percentages of IL-21+IL-17+ and IL-21-IL-17+ Th-cells
in ANCA-positive GPA patients did not differ from those
in ANCA-negative GPA-patients (Figure 1G and 1H).
These results suggest that persistence of IL-21+IL-17- Th-
cells during remission plays a role in the ongoing humoral
autoimmune response in ANCA-positive GPA patients.
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To rule out the possibility that the increased proportion
of IL-21+IL-17- Th-cells in GPA patients was the result of
current treatment, the ANCA-positive patient group was
divided into treated and untreated patients, and the percen-
tages of IL-21+IL-17- Th-cells were compared. No signifi-
cant differences were observed between treated and
untreated patients (data not shown). We also compared the
percentage of IL-21+IL-17- Th-cells between currently
untreated ANCA-positive patients with a history of general-
ized disease and those with localized disease. No difference
was found between these patient groups (data not shown).
Increased frequencies of IL-21+IL-17- Th-cells correlate
positively with Th17 response
It has been reported that IL-21 is a key factor regulating
the differentiation of naïve CD4+ T-cells into Th17 cells
[32,33]. In order to analyze this relationship, we tested
correlation between percentages of IL-21+IL-17- Th-cells
and percentages of terminally differentiated Th17 cells
(IL-21-IL-17+) in GPA patients (n = 42) and HCs (n =
29). Interestingly, a significant positive correlation was
observed between IL-21+IL-17- Th-cells and IL-21-IL-17+
Th-cells in both GPA patients and HCs (r = 0.58, P <
0.0001 and r = 0.37, P = 0.04, respectively) (Figure 2A
and 2B).
Increased frequencies of BCL-6+ CD4+ T-cells in peripheral
blood of ANCA-positive GPA patients
Since IL-21 is not the only marker for TFH cells, we
further characterized the identity of circulating IL-21-
producing cells by analyzing BCL-6 expression, which is
considered a master regulator and specific transcription
Figure 1 Multiparameter flow cytometric detection of IL-21 and IL-17 in circulating CD4+ T-cells in patients with granulomatosis with
polyangiitis (GPA) and healthy controls (HCs). Whole blood from GPA patients and HCs was stimulated with phorbol myristate acetate (PMA)/Ca-
ionophore and analyzed for intracellular IL-21 and IL-17 cytokine expression. Representative fluorescence-activated cell sorting (FACS)plots of IL-21
versus IL-17 expression in stimulated CD4+ T-cells from a GPA patient (right plot) and an age- and sex-matched HC (left plot) (A). Value in each gate
represents the percentages of cytokine producing cells. Percentages of total IL-21-producing Th-cells in peripheral blood of GPA patients (n = 42) and
HCs (n = 29) (B). Percentages of circulating IL-21+IL-17-, IL-21+IL-17+, and IL-21
-IL-17+ cells within the CD4+ T-cells in all GPA patients and HCs (C-E), or
in antineutrophil cytoplasmic antibody(ANCA)-positive (n = 23) and ANCA-negative (n = 19) GPA patients (F-H). Horizontal lines represent the median
percentage. P-values were calculated using the nonparametric Mann-Whitney U-test. *P < 0.05; ***P < 0.0005.
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factor for TFH cells [34,35]. To this end, the expression
of mRNA BCL-6 was assessed in circulating leukocytes
from GPA patients and HCs by real-time RT-PCR.
Restricted numbers of patients and controls were
included in this analysis due to insufficient cell numbers.
Patients with ANCA-positive GPA (n = 10) had a signif-
icantly higher expression of mRNA BCL-6 than ANCA-
negative patients (n = 6) and HCs (n = 11) (Figure 3B).
In addition, intracellular FACS-staining for BCL-6 within
circulating CD4+ T cells confirmed the increased BCL-6
expression in ANCA-positive GPA patients (Figure 3A
and 3C). We have also analyzed the MFI (mean fluores-
cence intensity) of BCL-6 expression in CD4+ T-cells
from patients and HCs and found that the expression
level of BCL-6 per Th-cell in GPA patients was similar to
that in HCs (data not shown). Thus, BCL-6 expression is
increased in GPA patients due to increased frequencies
of circulating BCL-6+ CD4+ T-cells.
Because in recent studies a new population of FoxP3+
regulatory T-cells has been described that shares features
with TFH cells by expressing the transcription factor BCL-
6, we also evaluated whether the increase in BCL-6+
T-cells in GPA patients was a result of an increase in
FoxP3+BCL-6+ T-cells [36,37]. This analysis showed that
the increase in BCL-6 expression in GPA patients was
restricted to TFH cells and although a low percentage of
FoxP3+BCL-6+ T-cells was found (< 0.3%), no differences
in these cell frequencies were observed between GPA
patients and HCs (data not shown).
Proportions of IL-21-receptor expressing B-cells do not
differ between GPA patients and healthy controls
Since it is well known that IL-21 acts on B-cells to sup-
port their expansion and antibody production [38-40],
we conducted further analysis to compare the expres-
sion of IL-21R on B cells from GPA patients and HCs.
No differences were seen in the percentages of IL-21R+
B-cells either between ANCA-positive (n = 13) and
ANCA-negative patients (n = 14) or between patients
and HCs (n = 19) (Figure 4).
IL-21 induces IgG and ANCA production by B-cells from
GPA patients
To explore the interplay between IL-21-producing Th-
cells and B-cells in GPA patients, we investigated the
effect of IL-21 on IgG antibody-production by B-cells
from GPA patients. Restricted numbers of patients and
controls were enrolled in this analysis due to insufficient
cell numbers. PBMCs from GPA patients were cultured
in vitro in the presence or absence of exogenous IL-21
for 12 days and total IgG was measured in supernatants
by ELISA. Because IL-21 promotes B-cell differentiation
by synergizing with BAFF [12,13], we questioned
whether the effect of IL-21 on IgG production could be
augmented by adding BAFF to the culture. Of note,
autologous T-cells in our culture system act as a natural
provider of CD40 ligation for B-cells, as this ligation is
required for B-cell activation, isotype switching and
memory development. As shown in Figure 5, IL-21 sig-
nificantly enhanced the production of IgG in vitro in sti-
mulated PBMCs from both ANCA-positive (n = 7) and
ANCA-negative (n = 6) GPA-patients, whereas stimula-
tion with BAFF alone did not result in increased IgG
production. The combination of BAFF and IL-21 tended
to increase IgG production more than IL-21 alone.
Next, we assessed the effect of IL-21 plus BAFF on in
vitro production of PR3-ANCA. As shown in Figure 5B,
spontaneous PR3-ANCA production was observed in
Figure 2 Correlation between the percentages of IL-21+IL-17- cells and IL-21-IL-17+ cells within the CD4+ T-cells in peripheral blood of healthy
controls (HCs) (A), and patients with granulomatosis with polyangiitis (GPA) (B). Spearman rank correlation coefficients (r) and P-values are given.
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cultured PBMCs from ANCA-positive patients (n = 16)
in comparison with cells from ANCA-negative patients
(n = 12). Importantly, IL-21 induces a significant
enhancement in PR3-ANCA production in PBMCs iso-
lated from ANCA-positive patients in comparison with
ANCA-negative patients. So it is conceivable that auto-
reactive B-cells were enriched in the peripheral blood of
ANCA-positive patients.
Discussion
In the present study, we demonstrate an increase in the
percentage of circulating IL-21-producing Th-cells in
GPA patients. We found that elevated frequencies of IL-
21-producing Th-cells were restricted to ANCA-positive
GPA patients and that these cells were distinct from
Th17-cells. We also confirmed that IL-21 can enhance
the production of IgG and ANCA in vitro.
Over the past few years, Th17-cells have challenged the
classical Th1/Th2 paradigm, and have been implicated in
a growing number of autoimmune and inflammatory dis-
eases [41]. Recently, a distinct Th-cell subset termed TFH
and characterized by elevated expression levels of multi-
ple surface proteins and BCL-6 as well as enhanced IL-21
secretion, have been identified as true helper cells for
antibody responses. We and others have previously
demonstrated that circulating Th17-cells are significantly
increased in GPA patients even during quiescent disease
[10,11]. However, data are lacking to support a role of
IL-21-producing Th-cells in GPA. Since Th17 cells also
produce IL-21, we investigated whether Th17 cells in
GPA are a source of IL-21. Strikingly, the majority of cir-
culating CD4 T-cells that produced IL-21 were distinct
from Th17 cells, indicating that other Th-cell subsets
such as TFH cells are the source of this cytokine. Impor-
tantly, the expansion of TFH cells in GPA patients was
confirmed by increased BCL-6 expression. To the best of
our knowledge, this is the first report demonstrating an
increase in the frequency of circulating IL-21-producing
Figure 3 Expression of transcription factors BCL-6 and FoxP3. (A) Representative FACS plots of BCL-6 versus FoxP3 expression in circulating
CD4+ T-cells from an antineutrophil cytoplasmic antibody (ANCA)-negative (right plot) and an ANCA-positive (middle plot) patient with
granulomatosis with polyangiitis (GPA), and an age- and sex-matched healthy control (HC) (left plot). Values in each gate represent the
percentages of positive cells. (B) Relative mRNA expression of BCL-6 in leukocytes from ANCA-positive (n = 10) and ANCA-negative (n = 6) GPA
patients, and age- and sex-matched HCs (n = 11) was analyzed by real-time reverse transcription-PCR normalized to the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). (C) Percentage of BCL-6+FoxP3- cells in circulating CD4+ T-cells was determined in ANCA-
positive (n = 11) and ANCA-negative (n = 10) GPA patients, and age- and sex-matched HCs (n = 10). Bars represent the mean values ± SD.
P-values were calculated using the nonparametric Mann-Whitney U-test. *P < 0.05; **P < 0.005.
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Figure 4 Comparison of IL-21R-expressing B-cells from patients with granulomatosis with polyangiitis (GPA) and healthy controls
(HCs). (A) Representative fluoresence-activated cell sorting (FACS) plots of IL-21R expression on CD19+ B-cells from an antineutrophil cytoplasmic
antibody (ANCA)-negative (right plot) and an ANCA-positive (middle plot) GPA patient, and an age- and sex-matched HC (left plot). Values in
each gate represent the percentages of IL-21R+ B-cells. (B) The percentage of IL-21R+ B-cells was determined in peripheral blood from ANCA-
positive (n = 13) and ANCA-negative (n = 14) GPA patients, and age- and sex-matched HCs (n = 19). Bars represent the mean values ± SD. P-
values were calculated using the nonparametric Mann-Whitney U-test.
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Th-cells in GPA, suggesting that TFH cell-derived IL-21
may contribute to disease pathogenesis via stimulation of
(auto)antibody production.
TFH cells are considered to be the major source of
IL-21 and seem to be an important subset for adaptive
immune responses, although there are conflicting
Figure 5 IL-21 induces in vitro immunoglobulin G (IgG) and proteinase 3 (PR3)-antineutrophil cytoplasmic antibody (ANCA)
production by B-cells from patients with granulomatosis with polyangiitis GPA. (A) PBMCs from ANCA-positive (n = 7) and ANCA-negative
(n = 6) GPA patients were cultured in the presence of rhIL-21 and/or rh B-cell activating factor (BAFF). Culture supernatants were collected after
12 days to measure total IgG by ELISA. (B) To assess the effect of IL-21 on in vitro ANCA-production, peripheral blood mononuclear ells (PBMCs)
from ANCA-positive (n = 16) and ANCA-negative (n = 12) GPA patients were stimulated in the presence of IL-21/BAFF. After 12 days, PR3-ANCA
levels were determined by Phadia ImmunoCAP® 250 analyzer. P-values were calculated using the Wilcoxon matched pairs test. *P < 0.05.
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reports on their mode of action in vivo. It has been
demonstrated that IL-21-producing Th-cells induce
Th17 development and proliferation [32,33], which has
been shown to promote germinal center (GC) formation
in a BXD2 mouse model of autoimmunity [42]. In
agreement with these findings, we demonstrate a signifi-
cant positive relationship between IL-17+IL-21- Th-cells
and IL-17-IL-21+ Th-cells in peripheral blood of GPA
patients. It seems likely that increased Th17 cells in
GPA-patients are the result of an enhanced TFH
response, which in turn may participate in granuloma
formation and vascular damage. The role of IL-21 in vas-
culitis was previously suggested by Chen and coworkers
[43]. In their study, mice deficient in interferon regula-
tory factor-4, a protein that inhibits IL-17A production,
rapidly developed large-vessel vasculitis and showed
increased IL-21 synthesis in addition to increased IL-17A
production [43]. Moreover, a role of IL-21 in recruitment
of Th17-cells to inflamed tissues has been reported by
Caruso and coworkers [44] by showing that IL-21
induces gut epithelial cells to secrete macrophage inflam-
matory protein-3a (MIP-3a), a chemokine that mediates
Th17-cell homing to the skin, joints, and mucosal tissues.
Given that endothelial cells are known to produce MIP-
3a, it is possible that IL-21 in GPA patients enhances the
migration and accumulation of Th17-cells into the vascu-
lar wall resulting in inflammation. Besides, IL-21 was
shown to enhance granzyme B expression [45] and
increase perforin-mediated cytotoxicity by human CD8
T-cells [46] and natural killer cells [47]. It is therefore
conceivable that IL-21 can contribute to vessel injury and
disease progression in GPA patients. This is an area
worth of further investigation.
In contrast to the pro-inflammatory role of TFH cells,
recent studies have identified a distinctive population of
TFH cells that displays a regulatory function and sup-
presses the differentiation of GC B-cells in follicles in vivo.
This subset was termed follicular regulatory T-cells (TFR),
which express the regulatory transcription factor FoxP3 in
addition to their specific lineage transcription factor BCL-
6 [36,37]. As circulating FoxP3+ T-cells are increased in
GPA patients [7], it is conceivable that the observed
increase in TFH cells in patients is due to an increase in
TFR cells that co-express FoxP3 and BCL-6. We have
investigated this possibility but found that the increase in
circulating TFH cells in GPA patients cannot be explained
by increase in TFR cells (data not shown).
In our study, increased frequencies of TFH cells were
observed in patients who were ANCA-positive at the
time of inclusion. This suggests the involvement of IL-
21 in the process of autoantibody production in GPA.
These data are in line with previous reports showing
that TFH cells act directly on B-cells through the IL-21/
IL-21R pathway, and that IL-21 is a potent inducer of
class-switch recombination and plasma cell differentia-
tion [39,48,49]. The expression of IL-21R on B-cells
from ANCA-positive and ANCA-negative GPA patients
was comparable, which suggests that both patient popu-
lations have the same ability to respond to IL-21.
However, in vitro stimulation with IL-21 enhanced the
production of ANCA in cell cultures from ANCA-
positive patients only, although enhanced total IgG-pro-
duction was observed in both patient groups. So it is
conceivable that autoreactive B-cells were enriched
in the peripheral blood of ANCA-positive patients. This
might be clinically relevant as well, because ANCA-
positive patients are at increased risk for disease relapse
[50,51].
In this study, patients were evaluated for the distribu-
tion of TFH cells during remission. We have previously
shown that activated T-cells are present at the time of
clinically quiescent disease [9,10]. Furthermore, during
active disease effector T-cells appear to migrate towards
inflamed tissue [52]. Therefore, in order to study dysba-
lance of T-cells in GPA patients using peripheral blood
samples, we choose to- select patients without or with
low dosages of immunosuppressive medication and at
the time of clinically quiescent disease.
Conclusions
In conclusion, the data presented here demonstrate a
prominent increase of circulating TFH cells in ANCA-
positive GPA patients. The key cytokine of these TFH
cells, that is IL-21, contributes to the production of
ANCA autoantibodies in vitro. These data support the
notion that TFH cells are associated with the pathogenic
process in GPA patients and may constitute a novel tar-
get for therapeutic intervention.
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